Business Description
ORIC Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US68622P1093
Total Employee Number:
104Description
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 85.54 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 9.3 | |||||
3-Year EPS without NRI Growth Rate | 11.5 | |||||
3-Year FCF Growth Rate | 13.2 | |||||
3-Year Book Growth Rate | -7.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -5.63 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.95 | |||||
9-Day RSI | 57.97 | |||||
14-Day RSI | 60.06 | |||||
3-1 Month Momentum % | -20.96 | |||||
6-1 Month Momentum % | -8.19 | |||||
12-1 Month Momentum % | -26.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 16.33 | |||||
Quick Ratio | 16.33 | |||||
Cash Ratio | 15.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.8 | |||||
Shareholder Yield % | -26.97 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -38.62 | |||||
ROA % | -36.22 | |||||
ROIC % | -140.34 | |||||
3-Year ROIIC % | -64.53 | |||||
ROC (Joel Greenblatt) % | -5808.47 | |||||
ROCE % | -42.29 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.64 | |||||
Price-to-Tangible-Book | 2.65 | |||||
EV-to-EBIT | -5.64 | |||||
EV-to-EBITDA | -5.68 | |||||
EV-to-FCF | -7.68 | |||||
| Price-to-Net-Current-Asset-Value | 4.1 | |||||
| Price-to-Net-Cash | 4.23 | |||||
Earnings Yield (Greenblatt) % | -17.73 | |||||
FCF Yield % | -9.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ORIC Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.238 | ||
| Beta | 1.3235 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 0.69 | ||
| Volatility % | 68.81 | ||
| 14-Day RSI | 60.06 | ||
| 14-Day ATR (€) | 0.308797 | ||
| 20-Day SMA (€) | 8.4172 | ||
| 12-1 Month Momentum % | -26.55 | ||
| 52-Week Range (€) | 6.1 - 13.3 | ||
| Shares Outstanding (Mil) | 103.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ORIC Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ORIC Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 125 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 32 days | ||
| General meeting for 2026 | 2026-06-18 08:00 | 7.03 (+0.00%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 08:00 | 6.42 (+0.00%) | ||
| Jefferies Global Healthcare Conference | 2026-06-03 11:40 | 6.79 (-1.82%) | ||
| First quarter earnings results for 2026 | 2026-05-04 | 7.99 (+0.00%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25 12:00 | 10.30 (+5.10%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-23 16:05 | 9.25 (-2.63%) | ||
| Annual report for 2025 | 2026-02-23 | 9.25 (-2.63%) | ||
| Guidance call for 2026 | 2026-02-18 14:30 | 8.35 (+0.60%) |
Show
Entries
ORIC Pharmaceuticals Inc Frequently Asked Questions
What is ORIC Pharmaceuticals Inc(FRA:4TZ)'s stock price today?
The current price of FRA:4TZ is €9.13. The 52 week high of FRA:4TZ is €13.30 and 52 week low is €6.10.
When is next earnings date of ORIC Pharmaceuticals Inc(FRA:4TZ)?
The next earnings date of ORIC Pharmaceuticals Inc(FRA:4TZ) is 2026-08-12 Est..
Does ORIC Pharmaceuticals Inc(FRA:4TZ) pay dividends? If so, how much?
ORIC Pharmaceuticals Inc(FRA:4TZ) does not pay dividend.
Press Release
Articles on ORIC Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers